

# CITATION REPORT

List of articles citing

Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience

DOI: 10.1093/annonc/mdh308  
Annals of Oncology, 2004, 15, 1179-86.

**Source:** <https://exaly.com/paper-pdf/36650472/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
270	Concurrent chemoradiotherapy for head and neck cancer. <b>2004</b> , 31, 786-93		15
269	Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study. <b>2005</b> , 22, 269-79		7
268	Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. <b>2005</b> , 93, 884-9		81
267	Curcumin suppresses growth of head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6994-7002	12.9	149
266	Reassessment of the role of induction chemotherapy for head and neck cancer. <b>2006</b> , 7, 565-74		48
265	Quality of life outcomes in laryngeal and oropharyngeal cancer patients after chemoradiation. <b>2006</b> , 135, 565-70		24
264	Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. <i>Oral Oncology</i> , <b>2006</b> , 42, 675-84	4.4	40
263	Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?. <b>2006</b> , 24, 2624-8		48
262	High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. <b>2006</b> , 24, 3438-44		16
261	Induction chemotherapy for larynx preservation: patient selection or therapeutic effect?. <b>2006</b> , 24, 540-3		14
260	Treatment of advanced head and neck cancer: what lessons have we learned?. <b>2006</b> , 24, 1023-5		35
259	Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. <b>2007</b> , 67, 8800-9		97
258	Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 35-45	7.5	50
257	Salvage re-irradiation for recurrent head and neck cancer. <b>2007</b> , 68, 731-40		197
256	Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. <b>2007</b> , 117, 2129-34		95
255	Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN). <i>Current Treatment Options in Oncology</i> , <b>2007</b> , 8, 252-60	5.4	4
254	Induction chemotherapy for squamous cancer of the head and neck. <b>2007</b> , 9, 129-33		2

253	Chemotherapy in the treatment of locally advanced head and neck cancer. <b>2008</b> , 97, 701-7		59
252	Head and neck cancer: an evolving treatment paradigm. <b>2008</b> , 113, 1911-32		146
251	Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer. <i>Head and Neck</i> , <b>2008</b> , 30, 346-50	4.2	6
250	Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. <b>2008</b> , 35, 251-61		38
249	Impact thérapeutique de l'acquisition cervicale d'âge en [18F]-FDG-TEP-TDM sur la prise en charge des carcinomes épidermoïdes de la tête et du cou. <b>2008</b> , 32, 473-481		
248	Head and neck cancer. <b>2008</b> , 371, 1695-709		1323
247	Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1650-4	10.3	39
246	Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1787-94	10.3	51
245	Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. <i>Annals of Oncology</i> , <b>2009</b> , 20, 921-7	10.3	106
244	Sensitive HPV detection in oropharyngeal cancers. <b>2009</b> , 9, 440		24
243	Targeted genetic and viral therapy for advanced head and neck cancers. <b>2009</b> , 14, 570-8		23
242	Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2009</b> , 31, 625-34	4.2	55
241	Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary. <i>Head and Neck</i> , <b>2009</b> , 31, 429-41	4.2	111
240	The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. <b>2009</b> , 115, 4586-94		83
239	Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. <b>2009</b> , 74, 1047-53		102
238	Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. <b>2009</b> , 73, 1293-303		105
237	Prevalence of head and neck cancers in Ahmedabad, Gujarat. <i>Indian Journal of Otolaryngology</i> , <b>2009</b> , 61, 4-10		3
236	Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. <b>2009</b> , 185, 775-81		37

235	[Radiotherapy, chemotherapy and target therapy for treatment of head and neck cancer : new developments]. <b>2009</b> , 57, 436-45		3
234	IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. <b>2009</b> , 73, 399-409		178
233	Radiochemotherapy in locally advanced squamous cell carcinomas of the head and neck. <b>2009</b> , 21, 525-31		15
232	Evaluation of 18F-FDG PET/CT for diagnosing cervical nodal metastases in patients with oral cavity or oropharynx carcinoma. <b>2009</b> , 108, 933-8		15
231	Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. <b>2009</b> , 36, 199-204		10
230	Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer?. <b>2009</b> , 91, 95-100		40
229	Surrogate endpoints in head and neck cancer. <b>2009</b> , 10, 309-10		2
228	Head and Neck Cancer. <b>2010</b> , 101-115		
227	Mononuclear phagocytes in head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2010</b> , 267, 335-44	3.5	11
226	MicroRNA as a Novel Modulator in Head and Neck Squamous Carcinoma. <b>2010</b> , 2010, 135632		17
225	Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. <b>2010</b> , 28, 8-14		191
224	Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. <b>2010</b> , 28, 2989-95		290
223	Predictors of competing mortality in advanced head and neck cancer. <b>2010</b> , 28, 15-20		268
222	Oropharyngeal cancer, human papilloma virus, and clinical trials. <b>2010</b> , 28, 1-3		65
221	Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. <b>2010</b> , 96, 94-9		47
220	Identifying the risk factors for late-stage head and neck cancer. <b>2011</b> , 11, 1321-5		28
219	Role of molecular markers in the management of head and neck cancers. <b>2011</b> , 23, 259-64		22
218	The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. <b>2011</b> , 34, 372-9		77

217	Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. <b>2011</b> , 34, 165-72		83
216	Long-term outcome and patterns of failure in patients with advanced head and neck cancer. <i>Radiation Oncology</i> , <b>2011</b> , 6, 70	4.2	43
215	ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. <b>2011</b> , 80, 1292-8		78
214	A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2304-9	10.3	46
213	Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2501-2507	10.3	19
212	Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced CT in the posttreatment setting. <b>2011</b> , 31, 355-73		21
211	Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. <b>2011</b> , 52, 24-31		69
210	Empowering induction therapy for locally advanced head and neck cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 773-781	10.3	12
209	Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1016-22	10.3	143
208	Comparison of ( 18 ) F-FLT PET and ( 18 ) F-FDG PET for detection of cervical lymph node metastases in head and neck cancers. <b>2012</b> , 132, 1347-54		9
207	Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients. <b>2012</b> , 2012, 754191		4
206	<sup>18</sup> F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. <b>2012</b> , 53, 1506-13		140
205	The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. <b>2012</b> , 2012, 761518		10
204	EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab. <b>2012</b> , 2012, 901320		6
203	Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. <b>2012</b> , 83, e377-83		25
202	Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). <b>2012</b> , 12, 483		9
201	Oropharynx cancer. <b>2012</b> , 36, 334-415		5
200	Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. <i>Oral Oncology</i> , <b>2012</b> , 48, 787-93	4.4	33

199	Molecular Characterization of Head and Neck Cancer. <i>Molecular Diagnosis and Therapy</i> , <b>2012</b> , 16, 209-222.5	20
198	Bilateral neck metastases in upper aero-digestive tract cancer: emphasis on the distribution of lymphatic metastases and prognostic implications. <b>2012</b> , 105, 553-8	2
197	Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , <b>2012</b> , 34, 1517-23 <sup>2</sup>	18
196	Preoperative predictive model of cervical lymph node metastasis combining fluorine-18 fluorodeoxyglucose positron-emission tomography/computerized tomography findings and clinical factors in patients with oral or oropharyngeal squamous cell carcinoma. <b>2012</b> , 113, 274-82	5
195	Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. <b>2013</b> , 13, 1065-72	6
194	The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. <b>2013</b> , 440, 701-6	28
193	Head and Neck Squamous Cell Cancer. <b>2013</b> , 61-75	
192	Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. <b>2013</b> , 119, 3462-71	67
191	Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. <b>2013</b> , 31, 744-51	196
190	Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. <i>Oral Oncology</i> , <b>2013</b> , 49, 872-877	4.4 52
189	Nodal status of central lymph nodes as a negative prognostic factor for papillary thyroid carcinoma. <b>2013</b> , 107, 777-82	19
188	Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. <b>2013</b> , 72, 837-43	10
187	Improved survival with HPV among African Americans with oropharyngeal cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2486-92	12.9 50
186	Competing roads to larynx preservation. <b>2013</b> , 31, 833-5	14
185	Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck. <b>2013</b> , 5, 1247-1253	19
184	Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e54736	3-7 47
183	An updated overview of HPV-associated head and neck carcinomas. <b>2014</b> , 5, 3956-69	83
182	The never-ending story: finding a role for neoadjuvant chemotherapy in the management of head and neck cancer. <b>2014</b> , 32, 2685-6	12

181	Tumor volume reduction rate measured during adaptive definitive radiation therapy as a potential prognosticator of locoregional control in patients with oropharyngeal cancer. <i>Head and Neck</i> , <b>2014</b> , 36, 499-504	4.2	22
180	Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , <b>2014</b> , 36, 474-80	4.2	39
179	Preclinical safety and activity of recombinant VSV-IFN- $\beta$ in an immunocompetent model of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , <b>2014</b> , 36, 1619-27	4.2	12
178	Pretreatment (18)F-FDG PET/CT in whole-body total lesion glycolysis to predict survival in patients with pharyngeal cancer treated with definitive radiotherapy. <b>2014</b> , 39, e296-300		13
177	Race and competing mortality in advanced head and neck cancer. <i>Oral Oncology</i> , <b>2014</b> , 50, 40-4	4.4	23
176	A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 216-25	10.3	220
175	The use of short segment free jejunal transfer as salvage surgery for cervical esophageal and hypopharyngeal cancer. <b>2014</b> , 38, 144-9		11
174	Adjuvant stereotactic body radiotherapy-cetuximab following salvage surgery in previously irradiated head and neck cancer. <b>2014</b> , 124, 1579-84		16
173	Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. <b>2014</b> , 32, 2735-43		352
172	Salvage surgery for head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2014</b> , 271, 1845-50	3.5	12
171	Effect of DJ-1 overexpression on the proliferation, apoptosis, invasion and migration of laryngeal squamous cell carcinoma SNU-46 cells through PI3K/AKT/mTOR. <b>2014</b> , 32, 1108-16		21
170	Circulating and disseminated tumour cells in head and neck cancer. <b>2015</b> , 129, 826-30		2
169	Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines. <b>2015</b> , 12, 3025-32		16
168	A clinical study of operation for advanced hypopharyngeal squamous cell carcinoma. <b>2015</b> , 25, 9-14		2
167	Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design. <i>Head and Neck</i> , <b>2015</b> , 37, 1583-9	4.2	16
166	Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes. <b>2015</b> , 7, 445-52		12
165	Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases. <b>2015</b> , 20, 455-62		16
164	HPV-Associated Head and Neck Cancer. <b>2015</b> , 107, djv344		112

163	Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. <i>Oral Oncology</i> , <b>2015</b> , 51, 957-62	4.4	42
162	The current role of systemic chemotherapy in the primary treatment of head and neck cancer. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 217-21	14.4	18
161	Risk stratification of metastatic neck nodes by CT and PET in patients with head and neck cancer receiving definitive radiotherapy. <b>2015</b> , 56, 183-9		14
160	18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes. <b>2015</b> , 10, 125-45		18
159	Induction chemotherapy followed by radiotherapy in patients with cervical lymph node metastases from unknown primary carcinoma. <b>2015</b> , 67, 74-8		2
158	Endoscopy-guided brachytherapy for sinonasal and nasopharyngeal recurrences. <b>2015</b> , 14, 419-25		17
157	Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. <b>2015</b> , 16, 346-51		26
156	Role of induction chemotherapy for N3 head and neck squamous cell carcinoma. <b>2015</b> , 42, 150-5		4
155	Emerging drugs for head and neck cancer. <b>2015</b> , 20, 313-29		23
154	Laryngeal preservation in ENT oncology. Retrospective series of 246 patients managed in the Caen University Hospital and François Baclesse Cancer Care Center between 1998 and 2008. <b>2015</b> , 132, 129-34		6
153	Pharmacotherapy of head and neck cancer. <b>2015</b> , 16, 2409-22		6
152	The effects of anesthesia on the morphoproteomic expression of head and neck squamous cell carcinoma: a pilot study. <b>2015</b> , 166, 674-82		11
151	Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. <b>2015</b> , 191, 656-64		20
150	Quid de la préservation laryngée en cancérologie ORL ? Étude rétrospective entre 1998 et 2008 sur 246 patients pris en charge au CHU de Caen et au centre François-Baclesse. <b>2015</b> , 132, 123-130		
149	Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis. <i>Head and Neck</i> , <b>2015</b> , 37, 670-6	4.2	10
148	Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study. <b>2015</b> , 20, 290-7		9
147	Image-guided high-dose-rate brachytherapy of head and neck - a case series study. <b>2016</b> , 8, 544-553		2
146	Neither high-dose nor low-dose brachytherapy increases flap morbidity in salvage treatment of recurrent head and neck cancer. <b>2016</b> , 8, 308-12		4

145	Molecular analyses of unselected head and neck cancer cases demonstrates that human papillomavirus transcriptional activity is positively associated with survival and prognosis. <b>2016</b> , 16, 367		2
144	Assessment of the Tumor Redox Status in Head and Neck Cancer by <sup>62</sup> Cu-ATSM PET. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155635	3.7	13
143	Comparison of the therapeutic effects of total laryngectomy and a larynx-preservation approach in patients with T4a laryngeal cancer and thyroid cartilage invasion: A multicenter retrospective review. <i>Head and Neck</i> , <b>2016</b> , 38, 1271-7	4.2	19
142	Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study. <b>2016</b> , 130, 833-42		4
141	The biological significance of methylome differences in human papilloma virus associated head and neck cancer. <b>2016</b> , 12, 4949-4956		6
140	Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. <b>2016</b> , 96, 21-9		24
139	Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 908-13	10.3	56
138	Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic. <i>Radiation Oncology</i> , <b>2016</b> , 11, 55	4.2	26
137	Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol. <i>Radiation Oncology</i> , <b>2016</b> , 11, 6	4.2	8
136	Chemotherapy in locally advanced head and neck squamous cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 44, 10-6	14.4	18
135	[Value of neck dissection before definitive radiation therapy for locoregionally advanced squamous cell carcinoma of the head and neck]. <b>2016</b> , 20, 18-23		2
134	Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. <b>2016</b> , 28, 50-61		14
133	Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors. <b>2017</b> , 19, 769-776		11
132	Reirradiation of head and neck cancer: Long-term disease control and toxicity. <i>Head and Neck</i> , <b>2017</b> , 39, 1122-1130	4.2	31
131	Revisiting induction chemotherapy before radiotherapy for head and neck cancer, part I: carcinoma of non-nasopharyngeal sites. <b>2017</b> , 13, 469-475		7
130	Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram. <b>2017</b> , 7, 43928		17
129	Distinct Angiogenic Changes during Carcinogenesis Defined by Novel Label-Free Dark-Field Imaging in a Hamster Cheek Pouch Model. <b>2017</b> , 77, 7109-7119		5
128	[Reirradiation of head and neck cancers]. <b>2017</b> , 21, 521-526		2

127	Comparison of Salvage Total Pharyngolaryngectomy and Cervical Esophagectomy Between Hypopharyngeal Cancer and Cervical Esophageal Cancer. <b>2017</b> , 24, 778-784		8
126	Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: single-institution experience and systematic review. <b>2017</b> , 103, 516-524		19
125	Re-irradiation for Recurrent Head and Neck Cancer. <b>2017</b> ,		
124	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. <b>2017</b> , 11, 2537-2549		4
123	Radiotherapy in the Management of Orofacial Cancer. <b>2017</b> , 324-338		1
122	Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. <b>2017</b> , 8, 55600-55612		73
121	Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck. <b>2018</b> , 128, 1594-1601		11
120	De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease. <b>2018</b> , 30, 146-151		9
119	Differential expression and prognostic value of long non-coding RNA in HPV-negative head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2018</b> , 40, 1555-1564	4.2	23
118	Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?. <b>2018</b> , 29, 287-294		2
117	Intratumoral injection of radioactive holmium-166 microspheres in recurrent head and neck squamous cell carcinoma: preliminary results of first use. <b>2018</b> , 39, 213-221		15
116	Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma. <b>2018</b> , 8, 6613		13
115	Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. <b>2018</b> , 47, 568-577		26
114	Adjuvant chemoradiation does not improve survival in elderly patients with high-risk resected head and neck cancer. <b>2018</b> , 128, 831-840		16
113	Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. <b>2018</b> , 144, 389-401		3
112	Value of extranodal extension detected by computed tomography for predicting clinical response after chemoradiotherapy in head and neck squamous cell cancer. <b>2018</b> , 138, 392-399		2
111	AHNS series: Do you know your guidelines? Guideline recommendations for recurrent and persistent head and neck cancer after primary treatment. <i>Head and Neck</i> , <b>2019</b> , 41, 7-15	4.2	3
110	The predictive factors of primary head and neck cancer stage at presentation and survival in a developing nation's tertiary hospital. <b>2018</b> , 6, 2050312118792416		4

109	Bioelectrical phase angle at diagnosis as a prognostic factor for survival in advanced head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2018</b> , 275, 2379-2386	3.5	25
108	Cancers of the Oral Cavity: Diagnosis and Treatment. <b>2018</b> ,		
107	Chemotherapy. <b>2018</b> , 291-313		
106	Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. <b>2018</b> , 132, 385-400		20
105	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). <b>2019</b> , 7, 184		223
104	Challenges in the re-irradiation of locally advanced head and neck cancers: outcomes and toxicities. <b>2019</b> , 8, 259-266		0
103	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. <b>2019</b> , 161, 635-642		12
102	Treatment outcomes for one-stage concurrent surgical resection and reconstruction of synchronous esophageal and head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2019</b> , 276, 2929-2940	3.5	5
101	Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine. <b>2019</b> , 10, 291-305		8
100	Squamous cell carcinoma of the head and neck - screening in patients who misuse alcohol and tobacco in Switzerland: a prospective pilot study. <b>2019</b> , 57, 1053-1057		3
99	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3152-3163	12.9	29
98	Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden. <i>Annals of Oncology</i> , <b>2019</b> , 30, 744-756	10.3	46
97	Guidelines in the Management of Advanced Carcinoma of the Larynx. <b>2019</b> , 77-98		
96	Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. <b>2019</b> , 18, 63		139
95	Prognostic value of C-reactive protein/albumin ratio for patients with hypopharyngeal and laryngeal cancer undergoing invasive surgery involving laryngectomy. <i>Head and Neck</i> , <b>2019</b> , 41, 1342-1350	4.2	12
94	High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2019</b> , 88, 9-15	4.4	18
93	Pretreatment ADC is not a prognostic factor for local recurrences in head and neck squamous cell carcinoma when clinical T-stage is known. <b>2020</b> , 30, 1228-1231		9
92	Rising incidence of late-stage head and neck cancer in the United States. <b>2020</b> , 126, 1090-1101		20

91	CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
90	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. <b>2020</b> , 21,		9
89	Diagnostic value of 3D dynamic contrast-enhanced magnetic resonance imaging in lymph node metastases of head and neck tumors: a correlation study with histology. <b>2020</b> , 9, 2058460120951966		1
88	A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. <b>2020</b> , 9, 1671-1682		10
87	Management of the irradiated N0-neck during salvage pharyngo-laryngeal surgery. <b>2020</b> , 46, 1059-1065		0
86	The presence of risk factors and corresponding treatment strategies post-surgical resection in stage IV hypopharyngeal squamous cell carcinoma patients: a retrospective cohort study. <b>2020</b> , 8, 189		5
85	The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. <i>Radiation Oncology</i> , <b>2020</b> , 15, 81	4.2	10
84	A qualitative examination of patient priorities and preferences during treatment decision-making for recurrent head and neck cancer. <b>2021</b> , 29, 377-385		1
83	Radical external beam re-irradiation in the treatment of recurrent head and neck cancer: Critical review. <i>Head and Neck</i> , <b>2021</b> , 43, 354-366	4.2	3
82	Prior chemoradiotherapy and pathological perineural invasion predict the survival outcomes of salvage surgery in head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2021</b> , 43, 874-883	4.2	3
81	Clinical features of head and neck cancer patients with brain metastases: A retrospective study of 88 cases. <i>Oral Oncology</i> , <b>2021</b> , 112, 105086	4.4	1
80	Multiparametric functional MRI and F-FDG-PET for survival prediction in patients with head and neck squamous cell carcinoma treated with (chemo)radiation. <b>2021</b> , 31, 616-628		13
79	Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer. <b>2021</b> ,		
78	Re-Irradiation for Local Relapses or Second Primaries: When and how?. <b>2021</b> , 247-275		
77	Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes. <b>2021</b> , 127, 1984-1992		1
76	Personalized automation of treatment planning in head-neck cancer: A step forward for quality in radiation therapy?. <b>2021</b> , 82, 7-16		5
75	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <b>2021</b> , 39, 840-859		42
74	Evaluation of head and neck cancer knowledge among the at-risk population of Karachi, Pakistan: a cross-sectional survey. <b>2021</b> , ahead-of-print,		

73	Biosafety, Nontoxic Nanoparticles for VL-NIR Photothermal Therapy Against Oral Squamous Cell Carcinoma. <b>2021</b> , 6, 11240-11247		2
72	The prognostic significance of survivin expression in patients with HNSCC: a systematic review and meta-analysis. <b>2021</b> , 21, 424		3
71	Automated Non-Coplanar VMAT for Dose Escalation in Recurrent Head and Neck Cancer Patients. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
70	Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. <i>Clinical and Translational Radiation Oncology</i> , <b>2021</b> , 28, 71-78	4.6	1
69	Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 97, 102192	14.4	3
68	Role of indocyanine green combined with radiotracer-Techneium 99m in neck surgery for primary and recurrent head and neck cancer: preliminary results of a tertiary cancer center. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2021</b> , 1	3.5	0
67	Perioperative high dose rate brachytherapy in head and neck cancers: case report and review of clinical application.. <i>BJR case Reports</i> , <b>2021</b> , 7, 20200158	0.7	
66	Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial. <i>European Journal of Cancer</i> , <b>2021</b> , 151, 201-210	7.5	0
65	Neutrophil-to-Lymphocyte Ratio as a Factor Predicting Radiotherapy Induced Oral Mucositis in Head Neck Cancer Patients Treated with Radiotherapy. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
64	Ribophorin II Overexpression Is Associated with Poor Response to Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in P16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
63	Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2021</b> , 121, 105480	4.4	2
62	Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2021</b> , 122, 105520	4.4	2
61	Hypoxia, Angiogenesis, and Oral Cancer Metastasis. <b>2009</b> , 299-321		1
60	Head and Neck Cancers. <b>2020</b> , 57-105		3
59	Biomarkers for Individualized Oral Cancer Therapy. <b>2015</b> , 43-60		1
58	Chemotherapy in Head and Neck Squamous Cell Cancer. <b>2016</b> , 53-68		1
57	Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2836-2845	8.8	54
56	PET/CT Imaging. <b>2011</b> , 2825-2891		3

55	Post-treatment F-FDG PET/CT for predicting survival and recurrence in patients with advanced-stage head and neck cancer undergoing curative surgery. <i>Oral Oncology</i> , <b>2020</b> , 107, 104750	4.4	3
54	Reirradiation using stereotactic body radiotherapy in the management of recurrent or second primary head and neck cancer: A meta-analysis and systematic review. <i>Oral Oncology</i> , <b>2020</b> , 107, 104757	4.4	5
53	Predictive value of quantitative F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma. <i>EJNMMI Research</i> , <b>2020</b> , 10, 102	3.6	10
52	Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis. <i>PLoS ONE</i> , <b>2012</b> , 7, e51526	3.7	16
51	Molecular characterization of head and neck cancer: how close to personalized targeted therapy?. <i>Molecular Diagnosis and Therapy</i> , <b>2012</b> , 16, 209-22	4.5	12
50	Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence. <i>Radiation Oncology Journal</i> , <b>2017</b> , 35, 1-15	2.5	30
49	Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study. <i>International Journal of Oncology</i> , <b>2017</b> , 51, 1471-1481	4.4	2
48	Induction chemotherapy of docetaxel and Cisplatin for the elderly patients with squamous cell carcinoma of the head and neck. <i>Cancer Research and Treatment</i> , <b>2007</b> , 39, 1-5	5.2	12
47	Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	3
46	Prevalence of head and neck cancers in Ahmedabad, Gujarat. <i>Indian Journal of Otolaryngology</i> , <b>2009</b> , 61, 4		
45	Cancer of the Oropharynx. <b>2010</b> , 546-587		
44	Multidisciplinary Management of Oropharynx Carcinomas. <b>2011</b> , 401-430		
43	Distinct Gene Profiles for Tumor and Non-Tumor Tissue in the Head and Neck: An Analytical Approach. <i>Journal of Cancer Science &amp; Therapy</i> , <b>2011</b> , S1, 1	5	
42	The Role of Chemotherapy in the Management of Patients with Locally Advanced Unresectable Head and Neck Cancer. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , <b>2013</b> , 64, 327-337	0	
41	Chemotherapy and molecularly targeted therapies for previously untreated SCCHN. <b>2013</b> , 80-99		
40	Concurrent Nimotuzumab with Radiation Therapy in Locally Advanced Cancers of Oropharynx and Hypopharynx: A Review of 6 Cases. <i>Journal of Cancer Therapy</i> , <b>2015</b> , 06, 390-398	0.2	
39	Treatment outcomes for hypopharyngeal squamous cell carcinoma in institutional review. <i>Japanese Journal of Head and Neck Cancer</i> , <b>2016</b> , 42, 44-50	0.1	
38	Conformal re-irradiation of recurrent head and neck tumors. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , <b>2016</b> , 5, 54	0.2	

37	Multidisciplinary Management of Oropharynx Carcinomas. <b>2016</b> , 475-510		
36	Permanent Interstitial Brachytherapy for Previously Irradiated Head and Neck Cancer. <i>Cureus</i> , <b>2018</b> , 10, e2517	1.2	5
35	Is There a Role for Induction Chemotherapy in the Treatment of Advanced Head and Neck Cancer?. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , <b>2019</b> , 351-358	0	
34	AN INSTITUTIONAL STUDY TO EVALUATE THE EFFICACY AND TOXICITY OF REIRRADIATION USING CONVENTIONAL RADIOTHERAPY FOR RECURRENT MALIGNANT DISEASE. <i>Journal of Evolution of Medical and Dental Sciences</i> , <b>2019</b> , 8, 174-176	0.1	
33	Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer. <b>2020</b> , 117-128		
32	High Dose-Rate Brachytherapy in Recurrent High-Risk Head and Neck Cancer. <b>2019</b> , 6,		
31	Screening von Kopf-Hals-Tumoren. <i>Springer Reference Medizin</i> , <b>2020</b> , 1-8	0	
30	Fibroblast growth factor receptors as therapeutic targets in head and neck squamous cell carcinomas. <b>2020</b> , 235-261		
29	Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy. <i>Acta Otorhinolaryngologica Italica</i> , <b>2012</b> , 32, 297-303	2.8	16
28	Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?. <i>Current Oncology</i> , <b>2022</b> , 29, 816-833	2.8	0
27	Induction Chemotherapy in Low-Risk HPV+ Oropharyngeal Cancer.. <i>Current Treatment Options in Oncology</i> , <b>2022</b> , 23, 54	5.4	
26	A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
25	Reirradiation for Rare Head and Neck Cancers: Orbit, Auditory Organ, and Salivary Glands.. <i>Cureus</i> , <b>2022</b> , 14, e22727	1.2	
24	Surgical stage in sequential therapy of unresectable oral cancer T3-4bN0-3M0: evaluation of treatment results. <i>Opuholi Golovy I Sei</i> , <b>2022</b> , 11, 41-49	0.2	
23	Survival and disease progression following solitary locoregional recurrence after head and neck radiotherapy.. <i>Head and Neck</i> , <b>2022</b> ,	4.2	
22	Re-irradiation for recurrent or second primary head and neck cancer.. <i>Radiation Oncology Journal</i> , <b>2021</b> , 39, 279-287	2.5	1
21	PET/CT Imaging in Squamous Cell Carcinoma of the Head and Neck. <b>2011</b> , 126-207		1
20	High-dose stereotactic radiotherapy boost in the treatment of squamous cell carcinoma of the head and neck region. <i>Radiation Oncology</i> , <b>2022</b> , 17,	4.2	

19	The Promise of Circulating Tumor DNA in Head and Neck Cancer. <i>Cancers</i> , <b>2022</b> , 14, 2968	6.6	1
18	Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 12,	5.3	1
17	Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: neoadjuvant and adjuvant approaches. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 102437	14.4	0
16	Prognostic Implications of Skin Invasion in Locally Advanced Oral Cavity Squamous Cell Carcinoma. 019459982211167		
15	Risk Factors for Fear of Recurrence in Head and Neck Cancer Patients.		
14	Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma.		
13	Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study.		1
12	Reirradiation for Head and Neck Cancer. <b>2022</b> , 153-172		0
11	Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer.		1
10	Spindle Cell Carcinoma of the Head and Neck: Clinical Characteristics and Molecular Signatures.		0
9	Whole-slide cytometric feature mapping for distinguishing tumor genomic subtypes in HNSCC whole slide images. <b>2022</b> ,		0
8	Recurrence prediction with local binary pattern-based dosiomics in patients with head and neck squamous cell carcinoma.		0
7	Diffusion-weighted imaging and apparent diffusion coefficient mapping of head and neck lymph node metastasis: a systematic review. 734-745		0
6	MicroRNA-4776-5p acts as a radiosensitizer and predicts the prognosis of patients with head and neck cancer receiving radiotherapy.		0
5	4th FY Khoo Memorial Lecture 2008: Nasopharyngeal Cancer Workgroup [The Past, The Present and The Future. <b>2008</b> , 37, 606-614		0
4	Magnetic Resonance with Diffusion and Dynamic Perfusion-Weighted Imaging in the Assessment of Early Chemoradiotherapy Response of Naso-Oropharyngeal Carcinoma. <b>2023</b> , 13, 2799		0
3	Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer. <b>2023</b> , 45, 1184-1193		0
2	A Clinical Study to Assess Diffuse Reflectance Spectroscopy with an Auto-Calibrated, Pressure-Sensing Optical Probe in Head and Neck Cancer. <b>2023</b> , 30, 2751-2760		0

- 1 Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate. **2023**, 12, 2979

o